-
Mashup Score: 0Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD - 28 day(s) ago
In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
Check out an interview with one of the lead investigators of the #EMERGENT trials, Rishi Kakar, MD, who discussed the promising 52-week data of #KarXT. https://t.co/l7AJaXqrGP https://t.co/cP4o809qqR